



Mouse Anti-Palivizumab monoclonal antibody, clone 3G23 (CABT-ZB229)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	CABT-ZB229 is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Palivizumab.
Specificity	This product is specific for Palivizumab.
Target	Palivizumab
Immunogen	Palivizumab
Isotype	IgG1, κ
Source/Host	Mouse
Clone	3G23
Purification	Protein A purified
Conjugate	Unconjugated
Applications	Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB228 - CABT-ZB229 Recommended Working Concentration: 0.005-0.5 µg/ml
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Format	Purified, Lyophilized.
Size	40 µg

Buffer	Lyophilized with PBS, pH 7.2, contains 0.02% sodium azide.
Preservative	0.02% sodium azide
Storage	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Ship	Wet ice

BACKGROUND

Introduction	Palivizumab with trade name Synagis, is an FDA-approved drug for the prevention of respiratory syncytial virus (RSV) infections. It is a recombinant humanized IgG1 kappa isotype monoclonal antibody. Palivizumab binds the RSV envelope fusion protein (RSV F) on the surface of the virus and blocking a critical step in the membrane fusion process.
Keywords	Mouse monoclonal antibody to Palivizumab/Synagis; HSDB 8178; MEDI 493; Palivizumab

GENE INFORMATION

Synonyms	Mouse monoclonal antibody to Palivizumab/Synagis; HSDB 8178; MEDI 493; Palivizumab
-----------------	--